scholarly journals P8‐170: A patient with ALK translocation‐positive lung adenocarcinoma in whom an EGFR mutation developed during the treatment with ALK inhibitors

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 354-355
Keyword(s):  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
Alk Inhibitors

Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement

2021 ◽  
pp. 030089162110055
Author(s):  
Dashi Zhao ◽  
Jun Fan ◽  
Li Peng ◽  
Bo Huang ◽  
Yili Zhu ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Egfr Mutations ◽  
Alk Rearrangement ◽  
Molecular Alterations ◽  
Anaplastic Lymphoma ◽  
Sporadic Cases ◽  
Epidermal Growth ◽  
Rare Group

Epidermal growth factor receptor ( EGFR) mutations and anaplastic lymphoma kinase ( ALK) rearrangements are considered mutually exclusive in non-small cell lung cancer (NSCLC), especially in lung adenocarcinoma (LUAC). However, sporadic cases harboring concomitant EGFR and ALK alterations have been increasingly reported. There is no consensus opinion regarding the treatment of patients positive for both molecular alterations. NSCLC with EGFR/ ALK coalterations should be separated into two subtypes: unifocal and multifocal LUAC. Here, we present an overview of the available literature regarding this rare group of patients to provide useful suggestions for therapeutic strategies.

scholarly journals EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

2016 ◽  
Vol 116 (2) ◽  
pp. 175-185 ◽  
Author(s):  
Yi-Long Wu ◽  
Lecia V Sequist ◽  
Cheng-Ping Hu ◽  
Jifeng Feng ◽  
Shun Lu ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Mutation Detection ◽  
Egfr Mutation ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma

2016 ◽  
Vol 16 (3) ◽  
pp. 489-498 ◽  
Author(s):  
Zehra Dilek Kanmaz ◽  
Gülfidan Aras ◽  
Esin Tuncay ◽  
Ayşe Bahadır ◽  
Celalettin Kocatürk ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Acrometastasis from an epidermal-growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma

2014 ◽  
Vol 2 (2-3) ◽  
pp. 21-23
Author(s):  
Mau-Ern Poh ◽  
Chong-Kin Liam ◽  
Jiunn-Liang Tan ◽  
Yong-Kek Pang ◽  
Chee-Kuan Wong ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Epidermal Growth

scholarly journals Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case

2014 ◽  
Vol 9 (5) ◽  
pp. e37-e39 ◽  
Author(s):  
Fumihiko Hirai ◽  
Mitsuhiro Takenoyama ◽  
Kenichi Taguchi ◽  
Ryo Toyozawa ◽  
Eiko Inamasu ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Rare Case ◽  
Egfr Mutation ◽  
Fusion Gene

scholarly journals Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

2011 ◽  
Vol 6 (11) ◽  
pp. 1962-1963 ◽  
Author(s):  
Sanjay Popat ◽  
Alexandra Vieira de Araújo ◽  
Toon Min ◽  
John Swansbury ◽  
Melissa Dainton ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
Alk Rearrangement ◽  
Exon 19

Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20588-e20588
Author(s):  
Linping Gu ◽  
Bei Zhang ◽  
Ding Zhang ◽  
Hong Jian
Keyword(s):  
Lung Adenocarcinoma ◽  
Egfr Mutation ◽  
De Novo ◽  
Egfr Mutations ◽  
Genomic Profiling ◽  
Small Cell Lung ◽  
Genetic Characteristics ◽  
Egfr Mutant ◽  
Lung Adenocarcinomas ◽  
Egfr T790m

e20588 Background: Transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is one of the resistance mechanism of EGFR tyrosine kinase inhibitors. However, the clinical course of transformed SCLC and the difference of genomic profiling between de novo SCLC patients and transformed SCLC patients are still poorly characterized. Methods: Patients from our hospital diagnosed with SCLC were enrolled retrospectively in this study, including de novo SCLC patients and SCLC patients transformed from EGFR-mutant lung adenocarcinomas. Genomic profiling was performed on formalin-fixed paraffin-embedded tumor samples by next generation sequencing (NGS). In statistical analysis, fisher ‘exact test was used. All tests were bilateral, with P<0.05 indicating significant statistical difference. Results: In total, 16 patients with SCLC transformed from EGFR-mutant lung adenocarcinomas and 230 de novo SCLC patients were included in our study. Transformed SCLC patients were more in younger (p=0.007), female (p<0.001) and non-smokers (p<0.001) than de novo SCLC patients. In transformed SCLC patients, 12 patients (75%) occurred SCLC transformation within 2 years after the lung adenocarcinomas diagnosis. Median transformation time was 20 months. During the treatment of adenocarcinomas, the overall response rate (ORR) was 75% and the median progression-free survival was 12 months. After the initiation of SCLC therapy, the ORR of 1st line chemotherapy was 40%. For the genomic profiling, EGFR mutations, including exon 19 deletion (56%), L858R (38%), and others (6%), were detected. 11 patients with acquired resistance were received EGFR T790M test, 82% of patients had acquired EGFR T790M mutation. 11 patients after transformation to SCLC had NGS test, 100% maintained their founder EGFR mutation, and other recurrent mutations included TP53, RB1 and EGFR amplification. Compared with the genetic alterations in de novo SCLC patients, TP53 mutations were significantly decreased (p=0.006) while EGFR mutations were significantly elevated (p<0.001) in transformed SCLC patients. However, no significant difference on RB1, ALK and ROS1 mutations were observed. Interestingly, a 60-year-old woman in our transformed SCLC cohort harbored EGFR 19 del mutant at allele frequency of 50.39%，she received osimertinib plus epirubicin/cyclophosphamide as 1st line treatment and reached partial response, with survival of 4 years to date. Conclusions: We demonstrated the clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC and found one patient still benefited from EGFR-TKI. Our study suggested that SCLC patients with EGFR mutation who transformed from lung adenocarcinoma may be potential benefit population using EGFR inhibitors.

Sign in / Sign up

Export Citation Format

Share Document